home / stock / avcn:cc / avcn:cc news

AVCN:CC News and Press, Avicanna Inc. From 01/17/23

Stock Information
Company Name: Avicanna Inc.
Stock Symbol: AVCN:CC
Market: TSXC
Website: avicanna.com
Menu
AVCN:CC AVCN:CC Quote AVCN:CC Short AVCN:CC News AVCN:CC Articles AVCN:CC Message Board
Get AVCN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AVCN:CC - Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of feminized Cannabis Seeds from Colombia to Spain

This export marks Avicanna’s 19 th new international market for Avicanna and the 16 th for Aureus branded products. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Jan. 17, 2023 (GLOBE NEWSW...
AVCN:CC - Avicanna Announces Organizational Change in Avicanna LATAM S.A.S

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ”...

AVCN:CC - Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ”...

AVCN:CC - Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto(TM) CBG Transdermal Gel Topical Product

TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based p...
AVCN:CC - Avicanna Commercializes 'Influid', a Proprietary Water-soluble technology in the Canadian Market

Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC beverage infuser under the Viola brand available in Ontario through the Onta...

AVCN:CC - Avicanna Reports Q3 2022 Financial Statement

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, November 14, 2022 (GLOBE N...

AVCN:CC - Avicanna Announces Extension of Term Loan

TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that...
AVCN:CC - Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-b...

AVCN:CC - Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain management, neurology, and dermatology, the portal is designed to address potential gap...

AVCN:CC - Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical ca...
Previous 10 Next 10